CONSISTENT SURVIVAL IMPROVEMENT WITH OSIMERTINIB IN EGFR-MUTATED NSCLC
In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib), in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced NSCLC. Interim overall survival data were encouraging but not formally statistically significant at […]
CONSISTENT SURVIVAL IMPROVEMENT WITH OSIMERTINIB IN EGFR-MUTATED NSCLC Read More »
